The global Frontotemporal Dementia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.
Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management. These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia.
According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause for Frontotemporal dementia is still unknown it majorly affects the individual between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives, increase in the number of research partnerships, presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.
Market Competition
Key players in the Frontotemporal Dementia Management market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
Know More About Report@ https://www.futuremarketinsights.com/reports/frontotemporal-dementia-management-market
Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey
Drug Class Type:
- Antidepressants
- Fluoxetine
- Fluvoxamine
- Sertraline
- Paroxetine
- Citalopram
- Bupropion
- Mirtazapine
- Antipsychotics
- Olanzapine
- Quetiapine
- Ziprasidone
- Aripiprazole
- Risperidone
- Paliperidone
End-Users:
- Hospitals
- Specialty clinics
- Others
Distribution Channel:
- Hospital Pharmacy
- Drug store
- Retail Pharmacy
- Online Pharmacy
- Others
Dementia is an umbrella term for a range of progressive conditions that affect the brain.
There are over 200 subtypes of dementia, but the five most common are: Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and mixed dementia.
This course is designed for any staff working with dementia sufferers in a health or social care setting.
According to the latest research by the company, the global frontotemporal disorders treatment market is expected to be valued at US$ 451.4 Mn, by 2028 end.
Government organizations such as the National Institute of Aging (NIA), National Institute of Neurological Disorders and Strokes (NINDS) and National Institute of Health (NIH) are conducting research and development support programs and making efforts to advance therapeutic development in neurological diseases.
Research funding initiatives by non-profit organization such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, CurePSP, Inc. have helped to promote FTD research initiatives.Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5033However, lack of approved drugs for frontotemporal disorder treatment is expected to negatively impact the growth of the frontotemporal disorders treatment market.
Moreover, the high failure rate of clinical trials and studies is also a major factor expected to hamper the growth of the frontotemporal disorders treatment market.The company has segmented the global frontotemporal disorders treatment market based on drug class, treatment type, disease indication, distribution channel, and regions.
Based on drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others.
In terms of revenue, the frontotemporal dementia segment is projected to hold significant share in the global frontotemporal disorders treatment market over the forecast period.
